HER-2 status in breast cancer: Correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 2, 2006, Pages 132-137

  Ciampa, Armando ^a   Xu, Bo ^a   Ayata, Gamze ^a   Baiyee, Daniel ^a   Wallace, Jan ^a   Wertheimer, Michael ^a   Edmiston, Kathryn ^a   Khan, Ashraf ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Automated Cellular Imaging System (ACIS); Fluorescent in situ hybridization (FISH); HER 2 neu; Immunohistochemistry

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; COMPUTER ASSISTED DIAGNOSIS; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; SCORING SYSTEM;

BREAST NEOPLASMS; FEMALE; FIXATIVES; FORMALDEHYDE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PARAFFIN EMBEDDING; RECEPTOR, ERBB-2;

EID: 33745346284     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000150516.75567.13     Document Type: Article

References (36)

1. Shih C, Padhy LC, Murray M, et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature. 1981;290:261-264.
2. Hynes NE, Stern DF. The biology of ErbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1994;1198:165-184.
3. Sundaresan S, Penuel E, Sliwkowski M. The biology of human epidermal growth factor receptor 2. Curr Oncol Rep. 1999;1:16-22.
4. Baselga J, Hammond LA. HER-2 targeted tyrosine-kinase inhibitors. Oncology. 2002;63(Suppl. 1):6-16.
5. Thomson TA, Hayes M, et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001;14:1079-1086.
6. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
7. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol. 1998;(abstr 376);17:97A.
8. Dittadi R, Brazzale A, Pappagallo G, et al. ErbB 2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res. 1997;17:1245-1247.
9. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992;10:1049-1056.
10. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer. 1994;73:2359-2365.
11. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10:599-605.
12. Stal O, Sullivan S, Wingren S, et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer. 1995;31A:2185-2190.
13. Tetu B, Brisson J, Plante V, et al. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol. 1998;11:823-830.
14. Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992;65:118-121.
15. Sjögren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16:462-469.
16. Borg A, Baldetorp B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 1994;81:137-144.
17. Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996;14:2702-2708.
18. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
19. Naber SP, Tsutsumi Y, Yin S, et al. Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma. Am J Clin Pathol. 1990;94:125-136.
20. Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA. 1992;89:5321-5325.
21. Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER- 2/neu oncogene amplification in primary breast cancer. J Clin Oncol. 1993;11:1936-1942.
22. Descotes F, Pavy JJ, Adessi GL. Human breast cancer: correlation study between HER-2/neu amplification and prognostic factors in an unselected population. Anticancer Res. 1993;13:119-124.
23. Gramlich TL, Cohen C, Fritsch C, et al. Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction. Am J Clin Pathol. 1994;101:493-499.
24. Youngson BJ, Anelli A, Van Zee KJ, et al. Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma. Am J Surg Pathol. 1995;19:1354-1358.
25. Dittadi R, Brazzale A, Pappagallo G, et al. ErbB 2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res. 1997;17:1245-1247.
26. Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999;17:1974-1982.
27. Cianciulli AM, Botti C, Coletti AM, et al. Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER- 2/neu in breast cancer. Cancer Genet Cytogenet. 2002;133:66-71.
28. Sijan W, Hossein SM, Frenkel EP, et al. Assessment of HER-2/neu status in breast cancer. Am J Clin Pathol. 2001;16:495-503.
29. Wedad H. Testing for HER2 status. Oncology. 2001;61(Suppl. 2):22-30.
30. Ridolfi RL, Jamehedor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000;13:866-873.
31. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291:1972-1977.
32. Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dualcolor and single-color scoring. Am J Clin Pathol. 2004;121:631-636.
33. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
34. Mass RD, Press M, Anderson S, et al. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol. 2001;20:22a.
35. Vogel CL, Cobleigh D, Tripathy D, et al. Superior outcomes with Herceptin (trastuzumab) (H) in fluorescence in situ hybridization (FISH)- selected patients. Proc Am Soc Clin Oncol. 2001;20:22a.
36. Smith IE. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs. 2001;12(Suppl. 4):S3-10.